Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows provided by (used in) operating activities:
Net earnings	$ 234.9	$ 19.5
Adjustments to reconcile net earnings to cash provided by operating activities:
Depreciation and amortization	787.3	428.1
Share-based compensation	45.9	34.7
Biomet merger consideration compensation expense		164.1
Intangible asset impairment	28.0
Income tax benefit from stock option exercises	26.8	77.7
Excess income tax benefit from stock option exercises		(10.3)
Inventory step-up	300.9	137.1
Gain on divestiture of assets		(8.9)
Changes in operating assets and liabilities, net of effect of acquisitions:
Income taxes	(152.2)	29.9
Receivables	(80.3)	29.4
Inventories	44.2	(196.5)
Accounts payable and accrued expenses	(76.0)	(293.8)
Other assets and liabilities	(154.5)	(23.7)
Net cash provided by operating activities	1,005.0	387.3
Cash flows provided by (used in) investing activities:
Additions to instruments	(251.3)	(186.0)
Additions to other property, plant and equipment	(130.1)	(118.6)
Purchases of investments	(1.4)	(179.0)
Sales of investments	273.3	578.8
Proceeds from divestiture of assets		57.9
Other business combination investments, net of acquired cash	(421.9)
Other investing activities	7.8	(19.6)
Net cash used in investing activities	(1,544.7)	(7,626.6)
Cash flows provided by (used in) financing activities:
Proceeds from senior notes		7,628.2
Proceeds from term loan	750.0	3,000.0
Redemption of senior notes		(2,740.0)
Payments on term loan	(700.0)	(150.0)
Net (payments) proceeds on other debt	(33.1)	0.8
Dividends paid to stockholders	(140.3)	(112.3)
Proceeds from employee stock compensation plans	113.5	77.0
Excess income tax benefit from stock option exercises		10.3
Restricted stock witholdings	(5.3)	(10.5)
Debt issuance costs	(3.4)	(58.4)
Repurchase of common stock	(415.5)
Net cash (used in) provided by financing activities	(434.1)	7,645.1
Effect of exchange rates on cash and cash equivalents	(10.2)	(22.2)
(Decrease) increase in cash and cash equivalents	(984.0)	383.6
Cash and cash equivalents, beginning of year	1,459.3	1,083.3
Cash and cash equivalents, end of period	475.3	1,466.9
Biomet [Member]
Cash flows provided by (used in) investing activities:
Business acquisition, net of acquired cash		$ (7,760.1)
LDR Holding Corporation [Member]
Adjustments to reconcile net earnings to cash provided by operating activities:
Biomet merger consideration compensation expense	24.1
Cash flows provided by (used in) investing activities:
Business acquisition, net of acquired cash	$ (1,021.1)